

Presynaptic CRF₁ Receptors Mediate the Ethanol Enhancement of GABAergic Transmission in the Mouse Central Amygdala

Zhiguo Nie¹, Eric P. Zorrilla², Samuel G. Madamba³, Kenner C. Rice⁴, Marisa Roberto², and George Robert Siggins^{3,*}

¹Burnham Institute for Medical Research, La Jolla, CA; ²Committee on the Neurobiology of Addictive Disorders and ³Department of Molecular and Integrative Neurosciences, and Alcohol Research Center, The Scripps Research Institute, La Jolla, CA; ⁴Chemical Biology Research Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD

E-mail: geobob@scripps.edu

Received July 22, 2008; Revised December 31, 2008; Accepted January 1, 2009; Published January 18, 2009

Corticotropin-releasing factor (CRF) is a 41-amino-acid neuropeptide involved in stress responses initiated from several brain areas, including the amygdala formation. Research shows a strong relationship between stress, brain CRF, and excessive alcohol consumption. Behavioral studies suggest that the central amygdala (CeA) is significantly involved in alcohol reward and dependence. We recently reported that the ethanol augmentation of GABAergic synaptic transmission in rat CeA involves CRF₁ receptors, because both CRF and ethanol significantly enhanced the amplitude of evoked GABAergic inhibitory postsynaptic currents (IPSCs) in CeA neurons from wild-type (WT) and CRF₂ knockout (KO) mice, but not in neurons of CRF₁ KO mice. The present study extends these findings using selective CRF receptor ligands, gene KO models, and miniature IPSC (mIPSC) analysis to assess further a presynaptic role for the CRF receptors in mediating ethanol effects in the CeA. In whole-cell patch recordings of pharmacologically isolated GABA_Aergic IPSCs from slices of mouse CeA, both CRF and ethanol augmented evoked IPSCs in a concentration-dependent manner, with low EC₅₀s. A CRF₁ (but not CRF₂) KO construct and the CRF₁-selective nonpeptide antagonist NIH-3 (LWH-63) blocked the augmenting effect of both CRF and ethanol on evoked IPSCs. Furthermore, the new selective CRF₁ agonist stressin₁, but not the CRF₂ agonist urocortin 3, also increased evoked IPSC amplitudes. Both CRF and ethanol decreased paired-pulse facilitation (PPF) of evoked IPSCs and significantly enhanced the frequency, but not the amplitude, of spontaneous miniature GABAergic mIPSCs in CeA neurons of WT mice, suggesting a presynaptic site of action. The PPF effect of ethanol was abolished in CeA neurons of CRF₁ KO mice. The CRF₁ antagonist NIH-3 blocked the CRF- and ethanol-induced enhancement of mIPSC frequency in CeA neurons. These data indicate that presynaptic CRF₁ receptors play a critical role in permitting or mediating ethanol enhancement of GABAergic synaptic transmission in CeA, via increased

*Corresponding author.

©2009 with author.

Published by TheScientificWorld; www.thescientificworld.com

vesicular GABA release, and thus may be a rational target for the treatment of alcohol abuse and alcoholism.

KEYWORDS: electrophysiology, alcohol, gamma aminobutyric acid, corticotrophin-releasing factor, corticotropin-releasing hormone, CRH, urocortin, stresscopin, whole-cell patch, IPSC

INTRODUCTION

Despite decades of research, the cellular and molecular mechanisms underlying the intoxicating and addictive properties of ethanol are not well understood. Synapses are considered to be the most sensitive site for central ethanol effects[2], in part because ethanol interacts with a number of transmitter-gated ion channels at relatively low concentrations. Postsynaptic γ -aminobutyric acid-A ($GABA_A$) receptors have received by far the most attention in this regard[2,3,4,5,6,7]. Generally, acute ethanol enhances $GABA_A$ ergic function in several central nervous system (CNS) areas, such as the nucleus accumbens, hippocampus, ventral tegmental area (VTA), and central amygdala (CeA). However, much recent evidence has shown that ethanol can also enhance $GABA$ ergic transmission presynaptically by enhancing $GABA$ release[2,3,5,7,8,9].

Corticotropin-releasing factor (CRF) and its paralogs urocortins 1, 2, and 3 are involved in stress responses, and are implicated in stress-related disorders, such as anxiety and depression[10,11,12,13,14]. CRF functions as a hormone in the hypothalamic-pituitary axis, releasing adrenocorticotrophic hormone (ACTH) from the anterior pituitary, and as a neurotransmitter in the CNS, mediating numerous behavioral stress responses. The CeA contains CRF receptors and abundant CRF-containing fibers[15,16](E. Crawford and G.R. Siggins, unpublished data); CRF itself is generally colocalized in CeA neurons together with $GABA$ [17,18]. Increased release of CRF can be measured in the CeA under conditions of acute stress[19,20,21,22] and decreases in stress reactions result when CRF receptor antagonists are injected into the CeA[20]. Direct electrical stimulation of, or microinjection of CRF into, the CeA produces physiological effects much like the stress response[23]. CRF-deficient mice show increased voluntary ethanol consumption following stress[24].

Low CRF concentrations can influence neuronal properties in the CNS (see, e.g., [25,26]). CRF decreases the slow afterhyperpolarizing potential in the hippocampus[25] and CeA[27], and enhances R-type voltage-gated calcium channels in rat CeA neurons[28]. These and other data[1,29,30] also suggest that CRF plays an important role in regulating synaptic transmission in the CNS. For example, in VTA dopamine neurons, CRF potentiates N-methyl-D-aspartic acid (NMDA)-mediated synaptic transmission via CRF_2 activation[30], and we recently found that CRF augments $GABA$ ergic inhibitory transmission in mouse CeA neurons via CRF_1 activation[1].

The CeA is a brain region intimately involved in alcohol dependence and excessive drinking[31,32]. During ethanol withdrawal, rats manifest behavioral analogues of anxiety correlated with increased CRF-like immunoreactivity in dialysates of the amygdala[19] and corresponding reductions in amygdala tissue content[33]. These behaviors are blocked by CRF antagonists injected into the CeA[34,35]. $GABA$ is the main inhibitory neurotransmitter in the adult mammalian CNS, including the rodent CeA. Behavioral studies have shown that a $GABA_A$ antagonist injected into the amygdala can decrease ethanol self-administration in dependent rats[36], and that CRF systems in the amygdala are activated during ethanol withdrawal[19,37].

In our laboratory, electrophysiological data showed that ethanol enhanced $GABA$ ergic transmission at both pre- and postsynaptic sites in a rat CeA slice[5], and that a similar ethanol augmentation of $GABA$ inhibitory postsynaptic currents (IPSCs) in mouse CeA required activation of CRF_1 receptors[1]. These combined data suggest that interactions between the CRF and $GABA$ ergic systems in the CeA may

play an important role in alcohol reward and dependence. Therefore, in the present study we have further explored the cellular site of CRF action and the receptor subtype involved in this interaction of ethanol with the CeA GABAergic system. Here, we report that ethanol and CRF both enhance GABAergic transmission via presynaptic CRF₁ receptor activation in the mouse CeA.

MATERIALS AND METHODS

Slice Preparation

We prepared amygdala slices from male C57Bl/6J mice as partly described previously[1], with slight modifications. All experiments were performed in accord with The Scripps Research Institute IACUC and NIH guidelines on the care and use of laboratory animals. Briefly, male mice (5–10 weeks old) were anesthetized with halothane (4%) and decapitated, and the brains rapidly removed into ice-cold artificial cerebrospinal fluid (ACSF) gassed with 95% O₂/5% CO₂ and containing (in mM): 130 NaCl, 3.5 KCl, 1.25 NaH₂PO₄, 1.5 MgSO₄·7H₂O, 2.0 CaCl₂, 24 NaHCO₃, and 10 *d*-glucose. We cut transverse slices 400 μm thick on a Leica VT 1000S vibrating cutter (McBain Instruments, Chatsworth, CA) and transferred them to a beaker containing ACSF bubbled with 95% O₂/5% CO₂ at room temperature. After incubation for at least 90 min, slices were transferred to the recording chamber. During recordings, slices were submerged and continuously superfused with ACSF at a rate of 2 ml/min. We performed most recordings at room temperature (~24°C), although we performed some experiments at 32°C. There were no differences for ethanol and CRF effects between slices held at 24 vs. 32°C.

Whole-Cell Recording

We made whole-cell patch-clamp recordings with pipettes pulled on a Sutter Instruments puller from borosilicate glass and containing (in mM): CsCl 130, HEPES 10, EGTA 10, MgCl₂ 1.0, and ATP 2.0, adjusted to pH 7.2–7.4 with CsOH 1.0. Recording electrode resistance was 3–5 MΩ. In most experiments, we visualized CeA neurons using an upright Olympus microscope with infrared illumination and Nomarski optics. We recorded neurons (mostly in the medial part of the CeA) using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA) and stored the data for later analysis using pClamp software (Molecular Devices). We clamped cells at –70 mV and monitored the series resistance continuously using small (10 mV) hyperpolarizing voltage steps (200 msec). We studied only those cells demonstrating <20 MΩ series resistance.

We evoked pharmacologically isolated GABA_A receptor-mediated IPSCs by stimulating locally within the lateral aspect of the CeA through a bipolar stimulating electrode placed near (<100 μm) the recording electrode, while superfusing the glutamate receptor blockers 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 10 μM) and DL-2-amino-5-phosphonovalerate (APV, 30 μM), and the GABA_B receptor blocker CGP 55845A (CGP, 1 μM). To confirm that the IPSCs were mediated by GABA_A receptors, at the end of most experiments we applied the GABA_A receptor antagonist bicuculline (30 μM) to verify block of the IPSCs. We also used a paired-pulse facilitation (PPF) protocol with an interstimulus interval of 50 msec and stimulus strength adjusted such that the amplitude of the first IPSC of the pair was 50% of maximal amplitude determined from input/output (I/O) relationships. We took measures before ethanol (control), during ethanol (5–15 min), and after ethanol washout (20–30 min) to calculate the amplitude of IPSCs or of the ratio between the second and first IPSCs. We express all values as mean ± SEM. We subjected data to a between-subjects or within-subject ANOVA with repeated measures and the Newman-Keuls post hoc test with *p* < 0.05 considered statistically significant. When appropriate, we used Student's paired or unpaired *t*-test.

Miniature IPSCs (mIPSCs)

For verification of presynaptic effects via mIPSC analysis, we examined two separate sets of CeA neurons using whole-cell recording either under infrared videomicroscopic guidance or in the “blind patch” configuration[38]. All recordings were made in the presence of 10 μM CNQX, 30 μM APV, 1 μM CGP, and 1 μM tetrodotoxin (TTX; to block action potential-driven spontaneous synaptic currents). All GABA_A mIPSC recordings were made with electrodes filled with an internal solution containing the following (in mM): 135 KCl, 10 HEPES, 2 MgCl₂, 0.5 EGTA, 5 ATP, and 1 GTP (the latter two added fresh on the day of recording), pH 7.2–7.3. The osmolarity of the solution was 275–290 mOsm. We analyzed the mIPSC data using Mini 5.1 software (Synaptosoft, Decatur, GA). Ethanol and CRF effects on frequency and amplitude within individual CeA neurons were evaluated using cumulative probability analysis[39], with statistical significance across grouped cells determined using a paired *t*-test ($p < 0.05$ considered significant).

Chemical and Drugs

We purchased DNQX and APV from Tocris Cookson (Ellison, MO), bicuculline from Sigma, ethanol from Remet (La Mirada, CA), and rat/human (r/h) CRF from American peptide (Sunnyvale, CA). To avoid loss of ethanol by evaporation, we diluted the ethanol in gassed ACSF from sealed stock solutions of reagent-grade 95% ethyl alcohol in water immediately before administration. CGP 55845A was a gift from Novartis Pharma (Basel). Astressin₂-B, stressin₁, and murine urocortin 3 (mUcn 3) were gifts from Jean Rivier and Wylie Vale (Salk Institute), and NIH-3, or LWH-63 (4-ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-*d*]pyrimidin-4-yl]amino-1-butanol), an analog of antalarmin, was synthesized by Dr. K. Rice, as previously described[40]. We found that equal concentrations (10 μM) of NIH-3 in the CeA of mice and antalarmin in rat CeA (Roberto et al., in preparation) were required to block a maximal concentration of CRF and ethanol.

RESULTS

CRF and Ethanol Dose Dependently Augment CeA IPSCs in Wild-Type and CRF₂-Knockout, but not CRF₁-Knockout, Mice

For analysis of the effects of r/hCRF and ethanol on GABAergic neurotransmission in the CeA, we prepared brain slices from CRF₁ knockout (KO) (Crhr1^{tm1Klee}/Crhr1^{tm1Klee}; [41]) or CRF₂ KO (Crhr2^{tm1Klee}/Crhr2^{tm1Klee}; [42]) mice and their wild-type (WT) littermates on a mixed C57BL/6J \times 129 background, as well as from C57BL/6J mice. Because we found that both r/hCRF and ethanol effects were equivalent in WT littermates and C57BL/6J mice, we have pooled the data for these two groups (hereafter referred to as WT mice).

To quantitate baseline effects of CRF and ethanol on evoked pharmacologically isolated GABA_Aergic IPSCs, and to estimate maximal and half-maximal (apparent EC₅₀) concentrations for subsequent tests, we performed concentration-response analyses of CeA neurons in slices taken from WT mice. Fig. 1 shows representative examples of the extent, time course, and concentration-response relationships obtained for r/hCRF and ethanol. CRF clearly increased the amplitude of the evoked IPSCs, with an apparent EC₅₀ of about 9 nM (Fig. 1C). As reported previously for rat[5] and mouse[1] CeA, ethanol increased the amplitude of GABA_A IPSCs, with an apparent EC₅₀ of about 12 mM (Fig. 1D). The logistic curve fits show roughly sigmoid shapes, as would be expected of simple ligand-receptor interaction. Notably, the maximal extent of augmentation of the mean IPSCs is about the same (~40%) for both CRF and ethanol.




FIGURE 1. CRF response (A), time course of action (B), and concentration-response relationships for augmentation of IPSCs by CRF (C) and ethanol (D) superfused onto neurons in CeA slices from WT mice. (A) Representative effect of 100 nM CRF superfusion on IPSCs of a medial CeA neuron; note the augmentation of IPSC size by CRF, with the usual recovery on CRF washout. Subsequent bicuculline (Bic) superfusion totally blocks the IPSC, indicating mediation by GABA_A receptors. (B) Time course of CRF action in another CeA neuron, showing a slow recovery from CRF after washout. (C and D) Pooled concentration-response data from five to eight neurons for each point. Points represent percent increase in mean (\pm SEM) IPSC peak amplitudes plotted against a log scale of drug concentrations. Solid curves are logistic fits of the data plotted by Origin software (ver. 7, OriginLab Corp, Northampton, MA), using $y = (A1 - A2) / [1 + (x/xo)^p] + A2$, where A1 is the initial value of IPSC increase (0–1%), A2 the estimated final maximum value (41% for CRF, 36% for ethanol), xo is the center x (8.5 for CRF; 12.3 mM for ethanol) value (unfixed), and p is the rate or power (1.8 for CRF; 3.3 for ethanol). All values were fixed except rate/power. Dashed lines indicate the apparent EC₅₀ for each agent: 9 nM for CRF and 12 mM for ethanol. Note the similar maximal effect of both agents. Values for the ethanol concentration-response curve taken from the dataset reported in Nie et al.[1].

In CeA neurons from WT mice, superfusion of 100 nM CRF, a maximally effective concentration, significantly ($F(1,9) = 6.96$, $p < 0.05$; $n = 9$) increased the amplitudes of GABA_Aergic IPSCs to 130–146% of control (Figs. 2A and B), equivalent to the CRF effects we reported previously[1]. In a separate set of eight neurons from WT mice, superfusion of 44 mM ethanol (a maximally effective concentration) also significantly ($F(1,14) = 7.32$, $p < 0.05$) enhanced the IPSCs to 131–142% of control (Figs. 2A and E). Neither CRF nor ethanol had any effect on holding currents or series resistance.




FIGURE 2. Both CRF and ethanol augment evoked GABAergic IPSCs in CeA neurons from WT and CRF₂ KO mice, but not those from CRF₁ KO mice. (A–C) Representative current records of individual evoked GABA_A IPSCs in CeA neurons from WT, CRF₁ KO, and CRF₂ KO mice. (A) Both 100 nM CRF and 44 mM ethanol increased the amplitudes of evoked IPSCs in two different CeA neurons from WT mice. (B) Superfusion of CRF and ethanol had no effect on evoked IPSCs in CeA neurons from CRF₁ KO mice. (C) By contrast, superfusion of both CRF and ethanol augmented evoked IPSCs in CeA neurons from CRF₂ KO mice. (D) Pooled data of the effect of 100 nM CRF on the mean amplitudes of GABA_A IPSCs. CRF 100 nM significantly ($p < 0.05$) enhanced the mean IPSC amplitude to $139 \pm 8\%$ of control in neurons from WT mice ($n = 8$) and to $139 \pm 7\%$ in neurons from CRF₂ KO mice ($n = 6$), but had no significant ($p > 0.05$) effect on mean IPSC amplitude in neurons from CRF₁ KO mice ($n = 6$). (E) Pooled data of the effect of 44 mM ethanol on mean GABA_A IPSC amplitudes. Ethanol significantly ($p < 0.05$) augmented the mean IPSC to $137 \pm 13\%$ of control in neurons from WT mice ($n = 7$) and to $141 \pm 9\%$ in CeA neurons from CRF₂ KO mice ($n = 7$), but had no significant ($p > 0.05$) effect in these neurons from CRF₁ KO mice ($n = 11$). * = $p < 0.05$.

We have also seen little evidence for desensitization of the CRF or ethanol effects either in rat (Roberto et al., in preparation) or mouse CeA (see also [1]). Indeed, in some cases, the CRF effect was difficult to “wash out” after a long exposure (Fig. 1B). To further explore this issue, we performed ethanol-CRF interaction studies using intracellular recording of WT mouse CeA. When we applied a maximal concentration (44 mM) of ethanol as control, followed by ethanol plus maximal CRF (200 nM), there was a further, but insignificant ($p = 0.12$, paired t -test; $n = 5$), increase in IPSC amplitude (EtOH alone, $120 \pm 12\%$; EtOH + CRF, $148 \pm 23\%$; washout, $108 \pm 14\%$). Such lack of summated effects (partial occlusion) would be expected if the two ligands act at least partially through the same mechanism. Similarly, when maximal CRF was superfused first, and then CRF plus maximal ethanol, a nonsignificantly greater mean IPSC amplitude was obtained than with CRF alone (CRF, $122 \pm 3\%$; CRF + EtOH, $141 \pm 12\%$; washout, $102 \pm 8\%$; $n = 7$, $p < 0.14$ by paired t -test). We tentatively interpret the apparent, but insignificant, summation as a possible indication of activation of, or allosteric changes in, CRF₁ receptors by ethanol.

We also re-examined the effects of CRF and ethanol on GABAergic transmission in CeA slices taken from CRF₁ KO mice (see also [1]). As shown in Figs. 2B and D, superfusion of 100 nM CRF had no significant effect on IPSCs in seven cells from the CRF₁ KO mice ($p > 0.05$). As reported [1], in another 11 cells from CRF₁ KO mice, superfusion of 44 mM ethanol also had no significant ($p > 0.05$) effect on the IPSCs (Figs. 2B and E). There were no differences between the amplitudes or shapes of GABAergic IPSCs evoked in the CeA of WT mice compared to CRF₁ KO mice (see Figs. 2A and B). Because both CRF and ethanol enhanced GABAergic IPSCs in CeA slices from WT mice, but not CRF₁ KO mice, we conclude that their effects involve CRF₁ receptors.

To determine if the enhancement of GABAergic IPSCs might also involve CRF₂ receptors, we have further examined the effect of CRF and ethanol on CeA neurons from CRF₂ KO mice. In six cells from these KO mice, superfusion of 100 nM CRF significantly ($F(1,10) = 6.17$, $p < 0.05$) increased GABAergic IPSC amplitudes to 132–141% of control (Figs. 2C and D), a level equivalent to that for the CeA of WT mice. In another six CeA neurons from CRF₂ KO mice, superfusion of 44 mM ethanol also significantly ($F(1,12) = 8.57$, $p < 0.05$) increased the IPSC amplitudes to 132–144% of control (Figs. 2C and E), also equivalent to that in WT mice. There was no difference in the baseline size or shape of IPSC amplitudes in WT mice compared to CRF₂ KO mice. These data suggest that CRF₂ receptors are not necessary for the r/hCRF or ethanol enhancement of GABAergic IPSCs in mouse CeA.

The CRF₁ Agonist Stressin₁, but not the CRF₂ Agonist mUcn 3, Augments Evoked IPSCs

To investigate further the role of CRF₁ receptors in IPSCs from mouse CeA, we applied stressin₁, a selective synthetic peptide agonist for CRF₁ [29,43], by superfusion onto slices from WT C57BL/6J mice. In five CeA neurons, 1 μ M stressin₁ significantly ($F(1,12) = 8.15$, $p < 0.05$) increased GABAergic IPSC amplitudes to 135–141% of control (Figs. 3A and B). As with r/hCRF, stressin₁ had no effect on holding currents in CeA neurons.

To assess further whether CRF₂ receptors might be involved in the r/hCRF effect, we examined the effect of the natural, highly selective, CRF₂ agonist mUcn 3 [44] on the CeA IPSCs. Superfusion of 1 μ M mUcn 3 had no effect on evoked IPSC amplitudes in any of the seven CeA neurons studied from WT mice (Figs. 3A and B). This negative finding also was obtained in slices in which Ucn 3 was applied first or in stressin₁-naïve neurons. These data support the hypothesis that r/hCRF and stressin₁ augment GABAergic IPSCs in CeA neurons via activation of CRF₁.




FIGURE 3. Stressin₁, but not Ucn 3, augments evoked GABAergic IPSCs in CeA neurons from WT mice. (A) Representative current traces of evoked IPSCs from a CeA neuron. Superfusion of 1 μM stressin₁ (Str₁, a selective CRF₁ agonist) increases the amplitude of evoked GABAergic IPSCs in this CeA neuron, with recovery to control levels on washout. In the same neuron, superfusion of 1 μM Ucn 3 (a selective CRF₂ agonist) has no effect on the IPSCs. Subsequent bicuculline (Bic; 30 μM) superfusion totally blocked the IPSCs, indicating that they were mediated by GABA_A receptors. (B) Pooled data: 1 μM stressin₁ significantly ($p < 0.05$) increased the mean amplitudes of evoked GABA_Aergic IPSCs in five CeA neurons from WT mice, with recovery to control levels on washout. However, 1 μM Ucn 3 had no significant effect on mean evoked IPSCs in seven CeA neurons from WT mice. * = $p < 0.05$.

A Selective CRF₁, but not CRF₂, Antagonist Blocks Ethanol and CRF Effects in CeA Neurons

We also determined whether CRF₁ or CRF₂ antagonists could block the CRF or ethanol augmentation of GABAergic IPSCs. In six of six cells from WT mice, superfusion of the selective nonpeptide CRF₁ antagonist NIH-3 (LWH-63; 10 μM) totally blocked the CRF-induced increase of evoked IPSC amplitudes in CeA slices (Figs. 4B and C). In seven of seven CeA neurons from WT mice, superfusion of 10 μM NIH-3 also totally blocked the usual ethanol-elicited increase of IPSC amplitudes in CeA neurons (Figs. 4A and B; compare to Fig. 2). Superfusion of 10 μM NIH-3 alone had little measurable effect on GABAergic IPSCs (Figs. 4A and B). Although 10 μM might seem to be a high NIH-3 concentration (see above for similar findings with the CRF₁ antagonist antalarmin), unpublished studies of rat CeA (Roberto et al., in preparation) indicate that the selective CRF₁ antagonist R121919, that is more water-soluble than NIH-3 or antalarmin, totally blocks CRF effects at 1.0 μM, as does the peptide antagonist D-phe-CRF₁₂₋₄₁ at 200 nM[1]. Further, the lack of CRF₂ involvement in the r/hCRF and ethanol augmentation of evoked GABAergic IPSCs suggested by the KO and agonist data above is supported further by our published data[1] showing that the selective CRF₂ antagonist astressin_{2,B}[45] had no effect on either the CRF- or ethanol-induced increase of IPSC amplitudes. Thus, the combined antagonist data further support the hypothesis that ethanol augmentation of evoked GABAergic IPSCs involves CRF₁, but not CRF₂, receptors in the mouse CeA.




FIGURE 4. A selective CRF₁ antagonist blocks ethanol and CRF effects on evoked IPSCs in CeA neurons. (A) Representative current records of evoked IPSCs from a CeA neuron. Superfusion of the CRF₁ antagonist NIH-3 (10 μM) alone has little direct effect on the IPSCs, but blocks the usual ethanol (A; 44 mM) and CRF (B; 100 nM) augmentation of evoked IPSCs in this CeA neuron from a WT mouse. (B) Pooled data of the effect of NIH-3 with ethanol or CRF on GABA_A IPSCs in CeA neurons from WT mice (n = 5). NIH-3 (10 μM) had no direct effect on the mean evoked IPSC amplitude, but significantly prevented the usual ethanol and CRF effects on mean amplitudes (compare to Figs. 1 and 2).

CRF and Ethanol Act at a Presynaptic Site to Increase IPSCs in Mouse CeA

Because CRF and ethanol could act at either pre- or postsynaptic sites to enhance IPSC size, we extended our previous studies of the PPF of GABAergic IPSCs (using an interstimulus interval of 50 msec, previously shown to be the most sensitive to ethanol effects[5,8]). In six of six CeA neurons from WT mice, superfusion of 100 nM CRF or 44 mM ethanol significantly decreased PPF of GABAergic IPSCs (Figs. 5A and C, left panel), consistent with our previous findings[1]. This effect suggests an increased GABA release from presynaptic terminals, because changes in PPF are known to be inversely related to transmitter release (i.e., a reduction of PPF is associated with an increased probability of transmitter release). By contrast, in four CeA cells from CRF₁ KO mice, superfusion of 44 mM ethanol had no significant ($p > 0.05$) effect on the PPF of GABAergic IPSCs (Figs. 5B and C), suggesting that ethanol acts presynaptically via activation of CRF₁ receptors. There was no evidence for a consistent difference in baseline PPF between CeA IPSCs of CRF₁ KO and WT mice.




FIGURE 5. Ethanol decreases the PPF of evoked GABA_A IPSCs (paired-pulse IPSCs evoked with interstimulus intervals of 50 msec) in CeA neurons from WT mice, but does not significantly effect PPF of IPSCs in CeA neurons from CRF₁ KO mice. (A) Representative current records of evoked IPSCs. Superfusion of 44 mM ethanol decreases the paired-pulse ratio of IPSCs (IPSC2 over IPSC1), to become paired-pulse inhibition, in a CeA neuron from a WT mouse, with recovery on washout. (B) Current records of evoked IPSCs: In a CeA neuron from a CRF₁ KO mouse, superfusion of 44 mM ethanol has little effect on the PPF of evoked IPSCs. (C) Pooled data comparing the effect of 44 mM ethanol on mean paired-pulse ratios of IPSCs from WT and CRF₁ KO mice. Ratios are expressed as percent of mean baseline value (100%). Ethanol 44 mM significantly decreased the mean PPF of IPSCs from WT mice, but had no significant effect on the PPF of evoked IPSCs from CRF₁ KO mice. * = statistical significance at $p < 0.05$ via ANOVA.

To further demonstrate that r/hCRF acts at presynaptic sites to enhance IPSC size, we recorded pharmacologically isolated, spontaneous mIPSCs in 1 μ M TTX. In six visually identified CeA neurons from WT mice, superfusion of 100 nM CRF significantly ($p < 0.05$) enhanced the frequency of mIPSCs (Figs. 6A and B) in the CeA from WT mice, but had little effect on the amplitude of mIPSCs (Figs. 6A and C). To confirm that this r/hCRF effect involves CRF₁, we tested the selective CRF₁ antagonist NIH-3. Superfusion of NIH-3 (10 μ M) alone only slightly decreased the frequency of mIPSCs in CeA slices. However, NIH-3 significantly inhibited the r/hCRF enhancement of mIPSC frequency (data not shown), suggesting that presynaptic CRF₁ receptors mediate the CRF enhancement of GABAergic synaptic transmission in mouse CeA neurons.




FIGURE 6. CRF enhances the frequency of spontaneous GABAergic mIPSCs in CeA neurons from WT mice. (A) Representative current traces recorded from a CeA neuron in the presence of $1 \mu\text{M}$ TTX and glutamate blockers. Superfusion of 100 nM r/hCRF clearly increases the frequency of the mIPSCs, with little obvious effect on their amplitude, with recovery on washout. Number of recorded events: Control, 9; CRF, 23; washout, 13. (B) Cumulative frequency histograms for a representative CeA neuron from WT mice showing a shift to the left, indicating briefer inter-event intervals (higher frequencies) during the application of 100 nM r/hCRF. (C) Cumulative amplitude histograms from the same CeA neuron showing little r/hCRF effect on the distribution of mIPSC amplitudes in CeA neurons from WT mice. Inset graphs are pooled data from six CeA neurons, showing that mean mIPSC frequency is significantly ($p < 0.05$) increased, but mean amplitude is not changed by CRF.

To minimize possible sampling bias of the visually identified neurons, we tested another set of CeA neurons using the “blind slice” or “blind patch” configuration. In these five CeA neurons, superfusion of 200 nM CRF significantly ($p < 0.05$) increased the frequency, but not the amplitude, of the mIPSCs (Figs. 7A–C), with recovery to control frequencies on washout of CRF (Fig. 7A). The findings suggest a lack of visual or cell-morphology bias in the sampling of CeA neurons with regard to the apparent presynaptic effects of CRF in increasing GABA release in CeA.

In another set of five CeA neurons, superfusion of 44 mM ethanol also significantly ($p < 0.05$) enhanced the frequency of mIPSCs in all five CeA neurons from WT mice (Figs. 8A and B), but only slightly and insignificantly ($p > 0.05$) decreased the amplitude of mIPSCs (Figs. 8A and C) in two cells, suggesting that ethanol increases GABAergic synaptic transmission in mouse CeA predominantly by a presynaptic mechanism, as in the rat CeA[5]. Superfusion of the CRF₁ receptor antagonist NIH-3 ($10 \mu\text{M}$) blocked the ethanol-induced increase of the frequency of mIPSCs in three cells (Fig. 8D), further indicating a role for presynaptic CRF₁ receptors in the ethanol augmentation of IPSCs.

DISCUSSION

These combined data suggest that an endogenous CRF₁ agonist and presynaptic CRF₁ receptors are involved in the ethanol augmentation of GABAergic transmission in CeA neurons. Thus, in the present studies, we




FIGURE 7. CRF increases the frequency of mIPSCs in WT murine CeA neurons recorded using the “blind patch” whole-cell configuration. All recordings performed in the presence of glutamate (DNQX 20 μ M and APV 30 μ M) and GABA_B (CGP 1 μ M) receptor antagonists and of 1 μ M TTX. (A) Representative current traces of mIPSCs from a CeA neuron with low baseline mIPSC frequency, showing that superfusion of 200 nM CRF (3 min) increased mIPSC frequency, with recovery after 9 min of washout (bottom trace). This neuron was held at -60 mV throughout the experiment. Number of recorded events: Control, 9; CRF, 14; washout, 6. (B) Cumulative event histograms of the same CeA neuron as in (A). Left panel: CRF increased the cumulative probability of mIPSCs with short inter-event intervals (greater frequency), with no effect on mIPSC amplitudes (right panel). (C) Pooled data from five WT mouse CeA neurons; 200 nM CRF significantly ($p = 0.002$) increased mean mIPSC frequency (by over 50%), but had no significant effect on mean mIPSC amplitude.




FIGURE 8. Ethanol increases the frequency of spontaneous mIPSCs in CeA neurons from WT mice. (A) Representative current traces recorded from a CeA neuron in the presence of glutamate blockers and TTX. Superfusion of 44 mM ethanol increases the frequency, but has little effect on the amplitude, of mIPSCs, with recovery on washout. Number of recorded events: Control, 14; ethanol, 31; washout, 17. (B) Cumulative frequency histogram of mIPSCs from a representative CeA neuron showing a shift to the left with ethanol, indicating a short inter-event interval (higher frequencies) during the application of 44 mM ethanol. (C) Cumulative amplitude histogram from the same CeA neuron showing a small, but insignificant ($p = 0.32$), decrease in the distribution of mIPSC amplitudes. Inset graphs in B and C are pooled data from six CeA neurons showing that mean mIPSC frequency is significantly increased ($p = 0.027$), but mean amplitude is only increased insignificantly ($p = 0.56$) by ethanol. (D) Current traces from another CeA neuron of a WT mouse. Superfusion of the CRF₁ antagonist NIH-3 (10 μ M) alone has little effect on mIPSCs, but blocks the ethanol enhancement of IPSC frequency in this neuron. Number of recorded events: Control, 22; NIH-3, 18; washout, 15.

have verified that sedating and intoxicating concentrations of ethanol augment GABAergic synaptic transmission in the CeA from WT and CRF₂ KO mice, but have virtually no effect on CeA GABAergic synaptic transmission in CRF₁ KO mice[1]. Further, in the present study, the selective CRF₁ agonist stressin₁, but not the CRF₂ agonist Ucn 3, augmented GABAergic transmission; also the selective CRF₁ antagonist NIH-3 blocked the ethanol enhancement of GABAergic synaptic transmission in WT mice, but the CRF₂ antagonist astressin_{2-B} had no effect on this enhancement. Both CRF and ethanol decreased PPF and increased the frequency of mIPSCs in CeA neurons from WT mice, but not the PPF in the CeA of CRF₁ KO mice, suggesting a role for presynaptic CRF₁ receptors in the ethanol effect. Because these

effects of ethanol on evoked IPSCs and PPF were completely absent in the CeA of CRF₁ KO mice, and ethanol effects on evoked and mIPSCs were blocked by the CRF₁ antagonist in the CeA of WT mice, presynaptic CRF₁ receptor activation appears to be necessary for these ethanol effects. Although little is known yet about the exact molecular mechanism(s) underlying the CRF₁ mediation of ethanol action, the effect appears to be action-potential independent. It is possible that ethanol increases GABA release from presynaptic terminals by triggering release of endogenous CRF that, in turn, activates CRF₁ receptors on GABAergic terminals to enhance quantal vesicular GABA release. Alternatively, ethanol could act directly on presynaptic CRF₁ receptors to increase GABA release[2].

GABA is the major inhibitory neurotransmitter in the CNS, and enhancement of GABAergic activity is a common property of many sedative and hypnotic drugs, including ethanol[2,3,4,5,46]. Although many previous behavioral and neurochemical studies focused on postsynaptic GABA_A receptors as important targets for ethanol action in the CNS, more recent electrophysiological studies have suggested that ethanol can also act on GABAergic terminals to increase GABA release presynaptically[2,5,9]. Behavioral studies have shown that injection of a GABA_A agonist into the CeA decreases ethanol self-administration in dependent rats[36]. Our lab recently reported electrophysiological data showing that ethanol increased GABAergic transmission at both pre- and postsynaptic sites in rat CeA neurons[5], and that ethanol significantly augmented evoked GABAergic IPSCs in mouse CeA neurons via a CRF₁ mechanism[1]. The present findings extend the mouse data to verify a presynaptic vesicular site of ethanol action in the mouse and further implicate activation of presynaptic CRF₁, but exclude requirement for CRF₂ receptors, in this ethanol effect.

The CRF system plays an important role in the regulation of anxiety-related behavior, and is implicated in anxiety and depressive disorders[13]. The biological actions of endogenous CRF and its structurally related paralogs (Ucns 1, 2, and 3) are mediated by two subtypes of G-protein-coupled receptors, CRF₁ and CRF₂, each with different splice variants, expression patterns, and physiological functions[14,47,48]. r/hCRF shows high CRF₁ and only moderate CRF₂ affinity, Ucn 1 acts on both CRF₁ and CRF₂ with high affinity, and Ucns 2 and 3 bind CRF₂ receptors selectively. Several lines of behavioral evidence point to the participation of CRF₁ receptors in mediating the stress-related effects of CRF. For example, CRF₁-deficient mice show reduced anxiety-related behavior[41,49], and administration of CRF₁, but not CRF₂, antisense oligodeoxynucleotides[50] or antagonists[50] also reduce anxiety-related behaviors. These and other data suggest that changes in the activity of CRF₁ receptor systems are involved in stress-related psychiatric disorders.

Much emerging evidence indicates an interaction between stress, brain CRF and GABA systems, and alcohol drinking[51,52,53,54]. Notably, the CRF system in the amygdala appears to be activated during stress and ethanol withdrawal, as evidenced by the increased CRF release measured by *in vivo* microdialysis[19], with resulting tissue content depletion[33]. The GABA system has provided a model for many anxiolytic pharmaceuticals, such as the benzodiazepines[55]. More recently, several studies have focused on the interaction between CRF and GABA. Interestingly, in the paraventricular nucleus (PVN), GABA appears to inhibit CRF secretion tonically[56]. Conversely, our studies suggest that CRF₁ receptor activation increases GABA release in the CeA. Although there is a reduction in extracellular GABA in the amygdala with conditioned fear stressors[57], exposure to predator stress increases CRF release in the PVN, and both CRF and GABA release in the amygdala[58]. In the latter study, injection of a CRF or GABA_A receptor antagonist into the amygdala immediately prior to stress had only a small effect on early stress responses, but significantly altered responses to repeat stress administered 2 days later, suggesting that release of both CRF and GABA in the amygdala is involved in plasticity following stress responses.

CONCLUSIONS

Our data indicate that CRF regulates or enhances GABA release from presynaptic terminals in the CeA slice. As GABA and CRF are colocalized in about half of the (mostly GABAergic) neurons in the

CeA[59], CRF₁ receptors could play a role as feedback autoreceptors that enhance GABA release from presynaptic terminals. However, the reported[60] low levels of mRNA for CRF₁ within the CeA may suggest that the increased GABA release could arise from activation of CRF₁ receptors on GABAergic terminals that arise from extrinsic sources, such as the basolateral amygdala or cortical amygdaloid nuclei. By increasing GABAergic inhibition of the CeA GABAergic interneurons, ethanol may disinhibit downstream components of the extended amygdala, such as the bed nucleus of stria terminalis.

As noted above, both CRF and GABA_A receptors are likely involved in anxiety and depression[61,62], and both disorders are implicated in excessive alcohol drinking in humans. Dysregulation of CRF₁ receptors may contribute to several stress-induced psychiatric disorders, such as human alcoholism[53,63], and numerous reports suggest that stressful life events and maladaptive responses elicit alcohol drinking and relapse behavior[64]. However, the molecular and cellular mechanisms underlying stress-induced alcohol drinking are still unknown. Our findings that both CRF and ethanol presynaptically enhance GABAergic transmission in a brain region known to be involved in stress-related behaviors provide a possible mechanism that links stress and depression/anxiety with ethanol reinforcement. Thus, our data support the hypotheses that CRF plays a crucial role in some behaviors associated with ethanol and that presynaptic CRF₁ receptors represent an important therapeutic target for the treatment of stress-related alcohol drinking.

ACKNOWLEDGMENTS

We thank Drs. G. Koob, P. Schweitzer, and S. Moore for helpful comments; T. Acosta for technical support; Drs. J. Rivier and W. Vale (Salk Institute) for the gift of stressin₁ and Ucn 3; Drs. K.-F. Lee and W. Vale (Salk Institute) for the receptor null mice; and Drs. W. Fröstl and A. Suter (Novartis Pharma) for the gift of CGP-55845A. This work was supported by NIH grants U01-AA10994 (under the INIA Consortium of the NIAAA), AA06420, DA03665, and NS38633. This work also was partially supported by the NIH Intramural Research Programs of the National Institute on Drug Abuse, the National Institute of Alcohol Abuse and Alcoholism, and the National Institute of Diabetes and Digestive and Kidney Diseases.

REFERENCES

1. Nie, Z., Schweitzer, P., Roberts, A.J., Madamba, S.G., Moore, S.D., and Siggins, G.R. (2004) Ethanol augments GABAergic transmission in the central amygdala via CRF1 receptors. *Science* **303**, 1512–1514.
2. Siggins, G.R., Roberto, M., and Nie, Z. (2005) The tipsy terminal: presynaptic effects of ethanol. *Pharmacol. Ther.* **107**, 80–98.
3. Criswell, H.E. and Breese, G.R. (2005) A conceptualization of integrated actions of ethanol contributing to its GABA_Amimetic profile: a commentary. *Neuropsychopharmacology* **30**, 1407–1425.
4. Deitrich, R.A., Dunwiddie, T.V., Harris, R.A., and Erwin, V.G. (1989) Mechanism of action of ethanol: initial central nervous system actions. *Pharmacol. Rev.* **41**, 489–537.
5. Roberto, M., Madamba, S.G., Moore, S.D., Tallent, M.K., and Siggins, G.R. (2003) Ethanol increases GABAergic transmission at both pre- and postsynaptic sites in rat central amygdala neurons. *Proc. Natl. Acad. Sci. U. S. A.* **100**, 2053–2058.
6. Ticku, M.K., Mhatre, M., and Mehta, A.K. (1992) Modulation of GABAergic transmission by ethanol. *Adv. Biochem. Psychopharmacol.* **47**, 255–268.
7. Weiner, J.L. and Valenzuela, C.F. (2006) Ethanol modulation of GABAergic transmission: the view from the slice. *Pharmacol Ther.* **111**(3), 533–554.
8. Roberto, M., Madamba, S.G., Stouffer, D.G., Parsons, L., and Siggins, G.R. (2004) Increased GABA release in the central amygdala of ethanol dependent rats. *J. Neurosci.* **24**, 10159–10166.
9. Roberto, M., Treistman, S.N., Pietrzykowski, A.Z., Weiner, J., Galindo, R., Mamedi, M., Valenzuela, F., Zhu, P.J., Lovinger, D., Zhang, T.A., Hendricson, A.H., Morrisett, R., and Siggins, G.R. (2006) Actions of acute and chronic ethanol on presynaptic terminals. *Alcohol. Clin. Exp. Res.* **30**, 222–232.

10. Keck, M.E., Welt, T., Muller, M.B., Landgraf, R., and Holsboer, F. (2003) The high-affinity non-peptide CRH1 receptor antagonist R121919 attenuates stress-induced alterations in plasma oxytocin, prolactin, and testosterone secretion in rats. *Pharmacopsychiatry* **36**, 27–31.
11. Heinrichs, S.C., Lapsansky, J., Lovenberg, T.W., De Souza, E.B., and Chalmers, D.T. (1997) Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. *Regul. Pept.* **71**, 15–21.
12. Chen, A., Zorrilla, E., Smith, S., Rousso, D., Levy, C., Vaughan, J., Donaldson, C., Roberts, A., Lee, K.F., and Vale, W. (2006) Urocortin 2-deficient mice exhibit gender-specific alterations in circadian hypothalamus-pituitary-adrenal axis and depressive-like behavior. *J. Neurosci.* **26**, 5500–5510.
13. Zorrilla, E.P. and Koob, G.F. (2004) The therapeutic potential of CRF1 antagonists for anxiety. *Expert Opin. Investig. Drugs* **13**, 799–828.
14. Zorrilla, E.P. and Koob, G.F. (2005) The roles of urocortins 1, 2 and 3 in the brain. In *Handbook of Stress, Immunology and Behaviour*. Steckler, T., Kalin, N.H., and Reul, J.M.H.M., Eds. Elsevier, New York. pp 179–203.
15. De Souza, E.B., Perrin, M.H., Insel, T.R., Rivier, J., Vale, W.W., and Kuhar, M.J. (1984) Corticotropin-releasing factor receptors in rat forebrain: autoradiographic identification. *Science* **224**, 1449–1451.
16. Uryu, K., Okumura, T., Shibasaki, T., and Sakanaka, M. (1992) Fine structure and possible origins of nerve fibers with corticotropin-releasing factor-like immunoreactivity in the rat central amygdaloid nucleus. *Brain Res.* **577**, 175–179.
17. Eliava, M., Yilmazer-Hanke, D., and Asan, E. (2003) Interrelations between monoaminergic afferents and corticotropin-releasing factor-immunoreactive neurons in the rat central amygdaloid nucleus: ultrastructural evidence for dopaminergic control of amygdaloid stress systems. *Histochem. Cell Biol.* **120**, 183–197.
18. Asan, E., Yilmazer-Hanke, D.M., Eliava, M., Hantsch, M., Lesch, K.P., and Schmitt, A. (2005) The corticotropin-releasing factor (CRF)-system and monoaminergic afferents in the central amygdala: investigations in different mouse strains and comparison with the rat. *Neuroscience* **131**, 953–967.
19. Pich, E.M., Lorang, M., Yeganeh, M., Rodriguez de Fonseca, F., Raber, J., Koob, G.F., and Weiss, F. (1995) Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. *J. Neurosci.* **15**, 5439–5447.
20. Gray, T.S. and Bingaman, E.W. (1996) The amygdala: corticotropin-releasing factor, steroids, and stress. *Crit. Rev. Neurobiol.* **10**, 155–168.
21. Roozendaal, B., Brunson, K.L., Holloway, B.L., McGaugh, J.L., and Baram, T.Z. (2002) Involvement of stress-released corticotropin-releasing hormone in the basolateral amygdala in regulating memory consolidation. *Proc. Natl. Acad. Sci. U. S. A.* **99**, 13908–13913.
22. Richter, R.M., Zorrilla, E.P., Basso, A.M., Koob, G.F., and Weiss, F. (2000) Altered amygdalar CRF release and increased anxiety-like behavior in Sardinian alcohol-preferring rats: a microdialysis and behavioral study. *Alcohol. Clin. Exp. Res.* **24**, 1765–1772.
23. Gray, T.S. (1993) Amygdaloid CRF pathways. Role in autonomic, neuroendocrine, and behavioral responses to stress. *Ann. N. Y. Acad. Sci.* **697**, 53–60.
24. Olive, M.F., Mehmert, K.K., Koenig, H.N., Camarini, R., Kim, J.A., Nannini, M.A., Ou, C.J., and Hodge, C.W. (2003) A role for corticotropin releasing factor (CRF) in ethanol consumption, sensitivity, and reward as revealed by CRF-deficient mice. *Psychopharmacology (Berl.)* **165**, 181–187.
25. Aldenhoff, J.B., Gruol, D.L., Rivier, J., Vale, W., and Siggins, G.R. (1983) Corticotropin releasing factor decreases postburst hyperpolarizations and excites hippocampal neurons. *Science* **221**, 875–877.
26. Siggins, G.R., Gruol, D., Aldenhoff, J., and Pittman, Q. (1985) Electrophysiological actions of corticotropin-releasing factor in the central nervous system. *Fed. Proc.* **44**, 237–242.
27. Rainnie, D.G., Fernhout, B.J., and Shinnick-Gallagher, P. (1992) Differential actions of corticotropin releasing factor on basolateral and central amygdaloid neurones, in vitro. *J. Pharmacol. Exp. Ther.* **263**, 846–858.
28. Yu, B. and Shinnick-Gallagher, P. (1998) Corticotropin-releasing factor increases dihydropyridine- and neurotoxin-resistant calcium currents in neurons of the central amygdala. *J. Pharmacol. Exp. Ther.* **284**, 170–179.
29. Liu, J., Yu, B., Neugebauer, V., Grigoriadis, D.E., Rivier, J., Vale, W.W., Shinnick-Gallagher, P., and Gallagher, J.P. (2004) Corticotropin-releasing factor and Urocortin I modulate excitatory glutamatergic synaptic transmission. *J. Neurosci.* **24**, 4020–4029.
30. Ungless, M.A., Singh, V., Crowder, T.L., Yaka, R., Ron, D., and Bonci, A. (2003) Corticotropin-releasing factor requires CRF binding protein to potentiate NMDA receptors via CRF receptor 2 in dopamine neurons. *Neuron* **39**, 401–407.
31. Koob, G.F. (2000) Neurobiology of addiction. Toward the development of new therapies. *Ann. N. Y. Acad. Sci.* **909**, 170–185.
32. Koob, G.F. and Nestler, E.J. (1997) The neurobiology of drug addiction. *J. Neuropsychiatry Clin. Neurosci.* **9**, 482–497.
33. Zorrilla, E.P., Valdez, G.R., and Weiss, F. (2001) Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats. *Psychopharmacology (Berl.)* **158**, 374–381.

34. Baldwin, H.A., Rassnick, S., Rivier, J., Koob, G.F., and Britton, K.T. (1991) CRF antagonist reverses the "anxiogenic" response to ethanol withdrawal in the rat. *Psychopharmacology* **103**, 227–232.
35. Rassnick, S., Heinrichs, S.C., Britton, K.T., and Koob, G.F. (1993) Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. *Brain Res.* **605**, 25–32.
36. Roberts, A.J., Schulteis, G., and Koob, G.F. (1996) Intra-amygdala muscimol decreases operant ethanol self-administration in dependent rats. *Alcohol. Clin. Exp. Res.* **20**, 1289–1298.
37. Valdez, G.R., Roberts, A.J., Chan, K., Davis, H., Brennan, M., Zorrilla, E.P., and Koob, G.F. (2002) Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. *Alcohol. Clin. Exp. Res.* **26**, 1494–1501.
38. Blanton, M.G., Lo Turco, J.J., and Kriegstein, A.R. (1989) Whole cell recording from neurons in slices of reptilian and mammalian cerebral cortex. *J. Neurosci. Methods* **30**, 203–210.
39. Van der Kloot, W. (1996) Statistics for studying quanta at synapses: resampling and confidence limits on histograms. *J. Neurosci. Methods* **65**, 151–155.
40. Hsin, L.W., Tian, X., Webster, E.L., Coop, A., Caldwell, T.M., Jacobson, A.E., Chrousos, G.P., Gold, P.W., Habib, K.E., Ayala, A., Eckelman, W.C., Contoreggi, C., and Rice, K.C. (2002) CRHR1 receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide corticotropin-releasing hormone type 1 receptor antagonists. *Bioorg. Med. Chem.* **10**, 175–183.
41. Smith, G.W., Aubry, J.M., Dellu, F., Contarino, A., Bilezikjian, L.M., Gold, L.H., Chen, R., Marchuk, Y., Hauser, C., Bentley, C.A., Sawchenko, P.E., Koob, G.F., Vale, W., and Lee, K.F. (1998) Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. *Neuron* **20**, 1093–1102.
42. Bale, T.L., Contarino, A., Smith, G.W., Chan, R., Gold, L.H., Sawchenko, P.E., Koob, G.F., Vale, W.W., and Lee, K.F. (2000) Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. *Nat. Genet.* **24**, 410–414.
43. Rivier, J., Gulyas, J., Kirby, K., Kunitake, K., Donaldson, C., Vaughn, J., Perrin, M., Koerber, S., Martinez, V., Tache, Y., Rivier, C., and Vale, W. (2001) Receptor-selective corticotropin-releasing factor analogs. *Soc. Neurosci. Abst.* **31**, 413.417.
44. Lewis, K., Li, C., Perrin, M.H., Blount, A., Kunitake, K., Donaldson, C., Vaughan, J., Reyes, T.M., Gulyas, J., Fischer, W., Bilezikjian, L., Rivier, J., Sawchenko, P.E., and Vale, W.W. (2001) Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. *Proc. Natl. Acad. Sci. U. S. A.* **98**, 7570–7575.
45. Rivier, J., Gulyas, J., Kirby, D., Low, W., Perrin, M.H., Kunitake, K., DiGrucchio, M., Vaughan, J., Reubi, J.C., Waser, B., Koerber, S.C., Martinez, V., Wang, L., Tache, Y., and Vale, W. (2002) Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. *J. Med. Chem.* **45**, 4737–4747.
46. Ticku, M.K. and Mhatre, M.C. (1992) Alcohol modulation of GABAA receptor function and gene expression. *Clin. Neuropharmacol.* **15**, 299A–300A.
47. Dautzenberg, F.M. and Hauger, R.L. (2002) The CRF peptide family and their receptors: yet more partners discovered. *Trends Pharmacol. Sci.* **23**, 71–77.
48. Reul, J.M. and Holsboer, F. (2002) Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. *Curr. Opin. Pharmacol.* **2**, 23–33.
49. Timpl, P., Spanagel, R., Sillaber, I., Kresse, A., Reul, J.M., Stalla, G.K., Blanquet, V., Steckler, T., Holsboer, F., and Wurst, W. (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. *Nat. Genet.* **19**, 162–166.
50. Skutella, T., Probst, J.C., Renner, U., Holsboer, F., and Behl, C. (1998) Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. *Neuroscience* **85**, 795–805.
51. Lodge, D.J. and Lawrence, A.J. (2003) The CRF1 receptor antagonist antalarmin reduces volitional ethanol consumption in isolation-reared fawn-hooded rats. *Neuroscience* **117**, 243–247.
52. Ryabinin, A.E., Bachtell, R.K., Heinrichs, S.C., Lee, S., Rivier, C., Olive, M.F., Mehmert, K.K., Camarini, R., Kim, J.A., Koenig, H.N., Nannini, M.A., Hodge, C.W., Roberts, A.J., and Koob, G.F. (2002) The corticotropin-releasing factor/urocortin system and alcohol. *Alcohol. Clin. Exp. Res.* **26**, 714–722.
53. Sarnyai, Z., Shaham, Y., and Heinrichs, S.C. (2001) The role of corticotropin-releasing factor in drug addiction. *Pharmacol. Rev.* **53**, 209–243.
54. Sillaber, I., Rammes, G., Zimmermann, S., Mahal, B., Zieglsangberger, W., Wurst, W., Holsboer, F., and Spanagel, R. (2002) Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1 receptors. *Science* **296**, 931–933.
55. Argyropoulos, S.V. and Nutt, D.J. (1999) The use of benzodiazepines in anxiety and other disorders. *Eur. Neuropsychopharmacol.* **9(Suppl 6)**, S407–412.
56. Bartanusz, V., Muller, D., Gaillard, R.C., Streit, P., Vutskits, L., and Kiss, J.Z. (2004) Local gamma-aminobutyric

- acid and glutamate circuit control of hypophyseotrophic corticotropin-releasing factor neuron activity in the paraventricular nucleus of the hypothalamus. *Eur. J. Neurosci.* **19**, 777–782.
57. Stork, O., Ji, F.Y., and Obata, K. (2002) Reduction of extracellular GABA in the mouse amygdala during and following confrontation with a conditioned fear stimulus. *Neurosci. Lett.* **327**, 138–142.
58. Foster, K.L., McKay, P.F., Seyoum, R., Milbourne, D., Yin, W., Sarma, P.V., Cook, J.M., and June, H.L. (2004) GABA(A) and opioid receptors of the central nucleus of the amygdala selectively regulate ethanol-maintained behaviors. *Neuropsychopharmacology* **29**, 269–284.
59. Veinante, P., Stoeckel, M.E., and Freund-Mercier, M.J. (1997) GABA- and peptide-immunoreactivities co-localize in the rat central extended amygdala. *Neuroreport* **8**, 2985–2989.
60. Van Pett, K., Viau, V., Bittencourt, J.C., Chan, R.K., Li, H.Y., Arias, C., Prins, G.S., Perrin, M., Vale, W., and Sawchenko, P.E. (2000) Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. *J. Comp. Neurol.* **428**, 191–212.
61. Macdonald, R.L. and Olsen, R.W. (1994) GABAA receptor channels. *Annu. Rev. Neurosci.* **17**, 569–602.
62. Lydiard, R.B. (2003) The role of GABA in anxiety disorders. *J. Clin. Psychiatry* **64(Suppl 3)**, 21–27.
63. Funk, C.K., Zorrilla, E.P., Lee, M.J., Rice, K.C., and Koob, G.F. (2006) Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. *Biol Psychiatry.* **61(1)**, 78–86.
64. Pohorecky, L.A. (1990) Interaction of alcohol and stress at the cardiovascular level. *Alcohol* **7**, 537–546.

This article should be cited as follows:

Nie, Z., Zorrilla, E.P., Madamba, S.G., Rice, K.C., Roberto, M., and Siggins, G.R. (2009) Presynaptic CRF₁ receptors mediate the ethanol enhancement of GABAergic transmission in the mouse central amygdala. *TheScientificWorldJOURNAL* **9**, 68–85. DOI 10.1100/tsw.2009.1.
